Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
On September 17, 2026, Calidi Biotherapeutics agreed to sell 1,025,640 common shares at $1.17 per share in a registered direct offering, which closed September 21, 2026, with gross proceeds of approximately $1.2 million before offering expenses. The company plans to use the net proceeds for working capital and general corporate purposes. The share sale increases the number of shares outstanding, and the company agreed not to issue additional equity for 45 days after closing.
Key points
- 1,025,640 shares sold at $1.17 per share, for gross proceeds of approximately $1.2 million before offering expenses.
- Offering closed September 21, 2026; no underwriter or placement agent was engaged, and no underwriting discounts or commissions were paid.
- Company agreed not to issue or sell equity or equity-linked securities for 45 days after closing, without consent of holders of more than 50% of the shares sold.
- Directors and executive officers agreed to 60-day lock-up agreements, subject to customary exceptions.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 22, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.